ENDRA Life Sciences Inc.(NDRA)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.5M in revenue and is scored on the micro-cap board instead.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
NDRA Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for ENDRA Life Sciences Inc. (NDRA), a Healthcare sector company. NDRA is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.5m in revenue and is scored on the micro-cap board instead. Top institutional holders of NDRA by reported 13-F value include Altium Capital Management, CITADEL ADVISORS, CITIZENS FINANCIAL GROUP, based on the most recent SEC filings. NDRA trades on the Nasdaq exchange and files with the SEC under CIK 1681682. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate NDRA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ENDRA Life Sciences Inc. directly from SEC EDGAR.
Net Income
Q2 2026
$159.9K
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
Net Income
+38.9% YoYOperating Income
+46.7% YoYEPS (Diluted)
+84.3% YoYTotal Assets
-13.4% YoYTotal Debt
Op. Cash Flow
+30.0% YoYFree Cash Flow
+29.9% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | $0.00 |
| Net Income | $-7.0M +38.9% | $-11.5M -14.4% | $-10.1M +23.7% | $-13.2M -17.3% | $-11.2M +4.2% | $-11.7M |
| Operating Income | $-5.8M +46.7% | $-10.8M -2.8% | $-10.5M +20.0% | $-13.2M -14.4% | $-11.5M +0.0% | $-11.5M |
| EPS (Diluted) | $-8.93 +84.3% | $-56.94 +97.9% | $-2766.85 | — | — | — |
| Total Assets | $3.9M -13.4% | $4.5M -34.1% | $6.8M -27.2% | $9.3M -28.0% | $12.9M +46.9% | $8.8M |
| Total Debt | — | $0.00 -100.0% | $28.5K -92.8% | $394.4K -27.8% | $546.6K | — |
| Operating Cash Flow | $-5.2M +30.0% | $-7.4M +22.5% | $-9.5M +25.2% | $-12.8M -14.8% | $-11.1M -3.5% | $-10.7M |
| Free Cash Flow | $-5.2M +29.9% | $-7.4M +22.6% | $-9.6M +26.1% | $-13.0M -16.2% | $-11.2M -3.2% | $-10.8M |
Get alerted when NDRA's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for ENDRA Life Sciences Inc. including:
Top Institutional Holders of NDRA
Altium Capital Management LP
$315.9K59,272 shCITADEL ADVISORS LLC
$159.5K29,924 shCITIZENS FINANCIAL GROUP INC/RI
$151.4K28,400 shGEODE CAPITAL MANAGEMENT, LLC
$79.5K14,910 shVANGUARD FIDUCIARY TRUST CO
$53.9K10,121 shVANGUARD CAPITAL MANAGEMENT LLC
$39.1K7,339 shMORGAN STANLEY
$18.9K3,546 shUBS Group AG
$362.0068 shTower Research Capital LLC (TRC)
$309.0058 shNORTHWESTERN MUTUAL WEALTH MANAGEMENT CO
$101.0019 sh
| Fund | Value | Shares |
|---|---|---|
| Altium Capital Management LP | $315.9K | 59,272 |
| CITADEL ADVISORS LLC | $159.5K | 29,924 |
| CITIZENS FINANCIAL GROUP INC/RI | $151.4K | 28,400 |
| GEODE CAPITAL MANAGEMENT, LLC | $79.5K | 14,910 |
| VANGUARD FIDUCIARY TRUST CO | $53.9K | 10,121 |
| VANGUARD CAPITAL MANAGEMENT LLC | $39.1K | 7,339 |
| MORGAN STANLEY | $18.9K | 3,546 |
| UBS Group AG | $362.00 | 68 |
| Tower Research Capital LLC (TRC) | $309.00 | 58 |
| NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | $101.00 | 19 |
More Healthcare Companies
View all Healthcare →Put NDRA on your watchlist
Track score changes the day ENDRA Life Sciences Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is NDRA a good stock to buy?
13F Pro's AI-powered analysis of ENDRA Life Sciences Inc. (NDRA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for NDRA are available on the NDRA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. NDRA is classified as a small company.
Which hedge funds own NDRA?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling NDRA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of ENDRA Life Sciences Inc.'s investment landscape.